Heart Diseases — Multidisciplinary Study of Right Ventricular Dysplasia
Citation(s)
Ainsworth CD, Skanes AC, Klein GJ, Gula LJ, Yee R, Krahn AD Differentiating arrhythmogenic right ventricular cardiomyopathy from right ventricular outflow tract ventricular tachycardia using multilead QRS duration and axis. Heart Rhythm. 2006 Apr;3(4):416-23.
Bowles NE, Ni J, Marcus F, Towbin JA The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2002 Mar 6;39(5):892-5.
Gear K, Marcus F Arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2003 Feb 4;107(4):e31-3.
Indik JH, Dallas WJ, Ovitt T, Wichter T, Gear K, Marcus FI Do patients with right ventricular outflow tract ventricular arrhythmias have a normal right ventricular wall motion? A quantitative analysis compared to normal subjects. Cardiology. 2005;104(1):10-5. Epub 2005 May 28.
Indik JH, Wichter T, Gear K, Dallas WJ, Marcus FI Quantitative assessment of angiographic right ventricular wall motion in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). J Cardiovasc Electrophysiol. 2008 Jan;19(1):39-45. Epub 2007 Sep 24.
Jain A, Tandri H, Calkins H, Bluemke DA Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Magn Reson. 2008 Jun 20;10:32. doi: 10.1186/1532-429X-10-32. Review.
Ly S, Marcus FI, Xu T, Towbin JA A woman with incidental findings of ventricular aneurysms and a desmosomal cardiomyopathy. Heart Rhythm. 2008 Oct;5(10):1455-7. doi: 10.1016/j.hrthm.2008.05.025. Epub 2008 May 29.
Marcus F, Towbin JA The mystery of arrhythmogenic right ventricular dysplasia/cardiomyopathy: from observation to mechanistic explanation. Circulation. 2006 Oct 24;114(17):1794-5.
Marcus FI, Zareba W, Sherrill D Evaluation of the normal values for signal-averaged electrocardiogram. J Cardiovasc Electrophysiol. 2007 Feb;18(2):231-3. Review.
Marcus FI Prevalence of T-wave inversion beyond V1 in young normal individuals and usefulness for the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Am J Cardiol. 2005 May 1;95(9):1070-1.
Scheinman MM, Crawford MH Echocardiographic findings and the search for a gold standard in patients with arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. 2005 Mar 15;45(6):866-7.
Vatta M, Marcus F, Towbin JA Arrhythmogenic right ventricular cardiomyopathy: a 'final common pathway' that defines clinical phenotype. Eur Heart J. 2007 Mar;28(5):529-30. Epub 2007 Feb 15.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.